Summary
We have measured plasma and synovial fluid concentrations of meclofenamic acid at 2, 4, 8, and 12 h during steady-state administration (100 mg three times daily for 4–7 days). Paired plasma and synovial samples were obtained pre-treatment and at one of the above times in twelve patients with a diagnosis of rheumatoid arthritis. In addition, the extent of protein binding of meclofenamic acid was assessed in vitro in the pre-treatment plasma and synovial fluid specimens.
Peak total concentrations of 1.73 and 0.86 µg·ml−1 were observed in plasma (at 2 h) and synovial fluid (at 4 h) respectively. The extent of protein binding was 99.7 and 99.6% (not significantly different) in plasma and synovial fluid respectively.
The results of this study are compared to those from similar reported studies of other nonsteroidal anti-inflamatory compounds.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wallis WJ, Simkin PA (1983) Antirheumatic drug concentrations in human synovial fluid and synovial tissue, observations on extravascular pharmacokinetics. Clin Pharmacokinet 8: 496–522
Fleishaker JC, McNamara PJ (1985) Performance of a diffusional clearance model for β-lactam antimicrobial agents as influenced by extravascular protein binding and interstitial fluid kinetics. Antimicrob Agents Chemother 28: 369–374
Fowler PD, Shadforth MF, Crook PR, John VA (1983) Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis. Eur J Clin Pharmacol 25: 389–394
Chan KKH, Kunjbala HV, Brandt KD (1987) In vitro protein binding of diclofenac sodium in plasma and synovial fluid. J Pharm Sci 76: 105–108
Wanwimolruk S, Brooks PM, Birkett DJ (1983) Protein binding of non-steroidal anti-inflammatory drugs in plasma and synovial fluid of arthritic patients. Br J Clin Pharmacol 15: 91–94
Fowler PD, Dawes PT (1985) Osmosin: Its effect on plasma and synovial fluid kinetics of indomethacin. Eur J Clin Pharmacol 27: 689–691
Emori HE, Champion GD, Bluestone R, Paulus HE (1973) Simultaneous pharmacokinetics of indomethacin in serum and synovial fluid. Ann Rheum Dis 32: 433–435
Gallo JM, Gall Eplasma, Gillespie WR, Albert KS, Perrier D (1986) Ibuprofen kinetics in plasma and synovial fluid of arthritic patients. J Clin Pharmacol 26: 65–70
Aarons L, Salisbury R, Alam-Siddiqi M, Taylor L, Grennan DM (1986) Plasma and synovial fluid kinetics of flurbiprofen in rheumatoid arthritis. Br J Clin Pharmacol 21: 155–163
Dromgoole SH, Furst DE, Desiraju RK, Nayak RK, Kirschenbaum MA, Paulus HE (1982) Tolmetin kinetics and synovial fluid prostaglandin E levels in rheumatoid arthritis. Clin Pharmacol Ther 32: 371–377
Boctor AM, Eickholt M, Pugsley TA (1986) Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukotrienes Med 23: 229–238
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koup, J.R., Thomas, D., Tucker, E. et al. Plasma and synovial fluid meclofenamic acid concentrations in patients with rheumatoid arthritis of the knee. Eur J Clin Pharmacol 35, 199–202 (1988). https://doi.org/10.1007/BF00609253
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00609253